Trials / No Longer Available
No Longer AvailableNCT04137822
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Impatients N.V. trading as myTomorrows · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
Detailed description
IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms. Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMM-101 | IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks. |
Timeline
- First posted
- 2019-10-24
- Last updated
- 2020-08-14
Locations
2 sites across 2 countries: France, United Kingdom
Source: ClinicalTrials.gov record NCT04137822. Inclusion in this directory is not an endorsement.